…
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Apellis Pharmaceuticals develops complement-targeting therapeutics; its lead drug pegcetacoplan is approved for geographic atrophy and paroxysmal nocturnal hemoglobinuria. Long-term growth may be driven by commercial uptake in ophthalmology and hematology, label expansions and advancement of next-generation complement programs. Investors may find the company attractive because it appears positioned in high‑unmet‑need indications with an approved therapy and a focused pipeline.
Key risks include uncertain commercial uptake and reimbursement, competition from other complement and ocular therapies, clinical and regulatory execution for pipeline programs and potential funding needs that could dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 24.11M | -196.72M | -526.50M | -651.50M | -746.00M |
| Net income | 22.39M | -197.88M | -528.63M | -652.17M | -746.35M |
| Selling general administrative | 550.26M | 417.75M | 500.81M | 277.16M | 176.77M |
| Selling and marketing expenses | - | 83.30M | 1.70M | - | - |
| Gross profit | 901.55M | 663.64M | 338.08M | 69.79M | 61.36M |
| Reconciled depreciation | 1.56M | 1.80M | 1.70M | 1.49M | 1.49M |
| Ebit | 68.44M | -156.32M | -496.92M | -594.61M | -536.28M |
| Ebitda | 70.00M | -154.53M | -495.21M | -584.50M | -533.00M |
| Depreciation and amortization | 1.56M | 1.80M | 1.70M | 10.11M | 3.27M |
| Operating income | 55.43M | -164.98M | -517.12M | -594.61M | -536.28M |
| Other operating expenses | 948.36M | 946.35M | 913.71M | 670.03M | 602.84M |
| Interest expense | 44.33M | 40.39M | 29.58M | 32.63M | 13.24M |
| Tax provision | 1.72M | 1.16M | 2.13M | 0.67M | 0.35M |
| Interest income | 13.14M | 12.77M | 20.93M | 8.91M | 0.42M |
| Net interest income | -31.18M | -27.62M | -8.65M | -23.71M | -12.82M |
| Income tax expense | 1.72M | 1.16M | 2.13M | 0.67M | 0.35M |
| Total revenue | 1003.78M | 781.37M | 396.59M | 75.42M | 66.56M |
| Total operating expenses | 846.12M | 828.62M | 855.20M | 664.40M | 597.64M |
| Cost of revenue | 102.24M | 117.72M | 58.51M | 5.64M | 5.20M |
| Total other income expense net | -31.32M | -31.74M | -9.38M | -56.89M | -209.72M |
| Net income from continuing ops | 22.39M | -197.88M | -528.63M | -652.17M | -746.35M |
| Net income applicable to common shares | - | - | - | -652.17M | -746.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1075.26M | 885.05M | 788.73M | 760.22M | 881.76M |
| Other current assets | 38.30M | 18.61M | 61.23M | 36.66M | 70.68M |
| Total liab | 705.11M | 656.51M | 594.21M | 590.35M | 683.10M |
| Total stockholder equity | 370.15M | 228.54M | 194.52M | 169.87M | 198.66M |
| Other current liab | 166.05M | 140.18M | 203.64M | 124.64M | 7.58M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -3012.98M | -3035.37M | -2837.49M | -2308.86M | -1656.69M |
| Other liab | - | - | - | 315.65M | 345.15M |
| Other assets | - | - | - | 15.80M | 31.64M |
| Cash | 467.76M | 411.29M | 352.30M | 551.80M | 640.19M |
| Total current liabilities | 323.60M | 185.51M | 247.59M | 167.61M | 131.85M |
| Current deferred revenue | - | - | - | - | 103.24M |
| Net debt | 18.55M | 58.49M | -241.37M | -439.09M | -429.97M |
| Short term debt | 100.75M | 6.75M | 6.44M | 5.62M | 4.12M |
| Short long term debt | 93.66M | - | - | - | - |
| Short long term debt total | 486.31M | 469.78M | 110.93M | 112.71M | 210.22M |
| Other stockholder equity | 3385.22M | 3267.20M | 3035.54M | 2479.60M | 1857.43M |
| Property plant equipment | - | - | - | 24.89M | 26.08M |
| Total current assets | 1014.84M | 788.95M | 766.33M | 719.52M | 824.05M |
| Net tangible assets | - | - | - | 169.87M | 198.66M |
| Short term investments | - | 4.85M | 4.35M | 0.00M | 60.36M |
| Net receivables | 366.22M | 271.72M | 206.44M | 7.73M | 10.10M |
| Long term debt | 361.66M | 452.83M | 93.03M | 92.74M | 189.02M |
| Inventory | 142.56M | 82.48M | 146.36M | 85.71M | 16.29M |
| Accounts payable | 56.80M | 38.57M | 37.52M | 37.34M | 16.91M |
| Accumulated other comprehensive income | -2.10M | -3.31M | -3.54M | -0.88M | -2.09M |
| Non currrent assets other | 40.51M | 77.06M | 1.31M | 15.80M | 31.64M |
| Non current assets total | 60.42M | 96.10M | 22.40M | 40.69M | 57.72M |
| Capital lease obligations | 19.03M | 16.95M | 17.89M | 19.98M | 21.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.40M | -0.67M | 59.89M | 248.72M |
| Change to liabilities | - | - | - | 18.69M | 10.49M |
| Total cashflows from investing activities | -0.31M | -0.40M | -0.67M | 59.89M | 247.62M |
| Net borrowings | 0.00M | 365.45M | 0.00M | - | - |
| Total cash from financing activities | 8.88M | 149.24M | 394.50M | 365.66M | 392.24M |
| Change to operating activities | - | - | - | 32.63M | -77.59M |
| Net income | 22.39M | -197.88M | -528.63M | -652.17M | -746.35M |
| Change in cash | 55.15M | 60.31M | -200.78M | -88.68M | 74.71M |
| Begin period cash flow | 412.61M | 352.30M | 553.07M | 641.75M | 567.04M |
| End period cash flow | 467.76M | 412.61M | 352.30M | 553.07M | 641.75M |
| Total cash from operating activities | 45.33M | -87.87M | -594.74M | -513.75M | -563.13M |
| Issuance of capital stock | 0.00M | 0.00M | 384.39M | 380.12M | 380.36M |
| Depreciation | 1.56M | 1.80M | 1.70M | 1.49M | 1.49M |
| Other cashflows from investing activities | -0.31M | - | 0.10M | - | - |
| Change to inventory | -15.27M | -10.76M | -60.65M | -69.40M | -16.32M |
| Change to account receivables | -101.28M | -58.48M | -198.72M | 2.38M | -10.10M |
| Sale purchase of stock | - | 4.51M | -11.04M | 4.24M | 2.97M |
| Other cashflows from financing activities | -0.01M | -235.04M | 10.11M | -18.70M | 8.90M |
| Change to netincome | - | - | - | 152.11M | 274.29M |
| Capital expenditures | 0.31M | 0.40M | 0.77M | 1.52M | 1.10M |
| Change in working capital | -85.12M | -18.36M | -200.17M | -15.70M | -93.52M |
| Stock based compensation | 104.00M | 114.13M | 105.94M | 91.08M | 70.67M |
| Other non cash items | 108.06M | 12.44M | 26.41M | 61.55M | 6.33M |
| Free cash flow | 45.01M | -88.27M | -595.51M | -515.27M | -564.23M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.80 1.91% |
40.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.08 0.39% |
535.71 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.09 0.95% |
961.49 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, Pres, CEO & Director | 1972 |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder & Chief Scientific Officer | 1970 |
| Dr. Federico Grossi M.D., Ph.D. | Co-Founder & Chief Medical Officer | 1974 |
| Mr. Alec Machiels J.D., MBA | Co-Founder & Director | 1973 |
| Mr. Timothy E. Sullivan | CFO & Treasurer | 1971 |
| Mr. Adam J. Townsend | Chief Commercial Officer | 1977 |
| Ms. Nur Nicholson | Chief Technical Operations Officer | NA |
| Mr. James G. Chopas CPA | VP, Corp. Controller & Chief Accounting Officer | 1966 |
| Ms. Meredith Kaya | Sr. VP, Investor Relations & Strategic Fin. | NA |
| Mr. David O. Watson Esq., J.D. | Gen. Counsel | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.